Tissue Regenix Group Regulatory News (TRX)

UK Patient receives world's first OrthoPure™ XM (dCELL® Meniscus) implant

5th March 2015

Tissue Regenix Ltd, the regenerative medical device company, is pleased to announce that for the first time a patient has successfully received a partial knee meniscal replacement using Tissue Regenix's OrthoPure XM. This has been done at Mount Vernon Hospital, Middlesex, as part of a clinical safety study by Tissue Regenix which is being conducted to secure a CE mark to enable launch of the product in the EU in 2016.

Mr David Houlihan-Burne performed the 'keyhole' surgical procedure that allows the surgeon to replace damaged sections of the knee meniscus with Tissue Regenix's decellularised tissue, which preserves the biomechanical properties of the tissue in a 'like for like' repair.

Tissue Regenix's OrthoPure XM will be used to repair damage from 'tears' in the meniscus knee cartilage as a result of acute injury or degeneration. Meniscal injuries affect around 1.5 million people per year in Europe and USA, and OrthoPure XM potentially addresses this substantial unmet clinical need.

Peter Hamer, Commercial Director of Orthopaedics at Tissue Regenix commented:

"It is early days with this trial but I am pleased the Ortho team have achieved this important milestone in our progress towards launch. We are fortunate to be working with surgeons who recognise the importance of innovative biologic solutions to this very common type of injury."

Enquiries:

Tissue Regenix Group plc Tel: 01904 435 176

Antony Odell, Chief Executive Officer

Ian Jefferson, Chief Financial Officer

Tulchan Communications Tel: 020 7353 4200

Tom Buchanan / Victoria Huxster